Upstream Bioprocessing Market Size (2024 - 2029)

Upstream Bioprocessing Market Analysis

The upstream bioprocessing market is expected to register a CAGR of 5.5% over the forecast period.

• The COVID-19 pandemic significantly impacted the upstream bioprocessing market, as drug manufacturers focused on developing vaccines and medications for COVID-19 diagnosis and treatment. The need for efficient development of new upstream bioprocesses became more crucial during the pandemic. This resulted in a surge in upstream bioprocessing rates, which contributed to market growth. However, as COVID-19 cases decline, the market is stabilizing, returning to pre-pandemic levels.
• Over the forecast period, the rising adoption of single-use upstream bioprocessing, commercial success and demand for biotherapeutics, and increasing research activities are expected to drive the market's growth. Advanced upstream bioprocessing technologies are essential in developing and scaling up manufacturing operations and analytical testing capabilities. These processes are crucial in the research activities to develop biosimilars, therapeutic peptides, and monoclonal antibodies. Upstream bioprocessing's contamination-free, safe, and efficient production further propels the market. With solid investments in R&D activities and a pipeline of therapeutics under development, upstream bioprocessing is expected to grow significantly.
• The increasing investment in research and development by phramceutical industry across the world is also expected to contribute to the growth of the market. For instance, according European Federation of Pharmaceutical Association the research and development expenditure incureeed in Europe by Pharmaceutical industry was EUR 42.53 billion (USD 44.72 billion) in 2022 and This is expected to increase to EUR 44.50 billion (USD 46.79 billion) in 2023. Such increase in R&D also creates need for the upsteam bioprocessing products and hence expected to propel the growth of the market.
• The launch of technologically advanced and innovative products also drives the market's growth. For example, Thermo Fisher Scientific launched its new Gibco Human Plasma-like Medium (HPLM) to provide researchers with a realistic view of cell growth within the human body. Nucleus Biologics launched Krakatoa, which is a creative, one of the first-to-market media makers that help researchers manufacture cell culture media at the point of use.
• Although the market has promising growth potential, operational challenges regarding upstream bioprocessing are expected to restrain the market's growth over the forecast period.

Upstream Bioprocessing Industry Segmentation

As per the scope, upstream bioprocessing involves using living cells to obtain desired products. This process starts from early cell separation and cultivation to cell culture expansion to harvest the final product.

The upstream bioprocessing market is segmented by product (cell culture products, bioreactors/fermenters, filters, bioreactors accessories, and other products), usage type (single-use and multi-use), mode (in-house and outsourced), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers the value (in USD) for the above segments.